More To Go Or Is It Over? – Biogen Inc. (BIIB)

Biogen Inc. (NASDAQ:BIIB) does about 1.15M shares in volume on a normal day but saw 782852 shares change hands in Friday trading. The company now has a market cap of 40.18B USD. Its current market price is $278.38, marking an increase of 2.52% compared to the previous close of $271.53. The 52 week high reached by this stock is $311.88 whilst the lowest price level in 52 weeks is $187.16. The script in recent trading has seen the stock touch a high of $278.86 and a low of $269.25.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Biogen Inc. (BIIB) has a 20-day trading average at $287.23 and the current price is -10.74% off the 52-week high compared with 48.74% distance from its 52-week low. The 50-day simple moving average of the closing price is $284.43 and its 200-day simple moving average is $244.00. If we look at the stock’s price movements over the week, volatility stands at 3.39%, which decreases to 2.39% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.74 to suggest the stock is neutral.

31 analysts observing the Biogen Inc. (BIIB) stock have set the 12-month price targets for the company’s shares at between $249.00 and $388.00. The consensus objective for the share price is $322.26, suggesting that the stock has a potential upside of 13.62% over the period. The median price target is 14.34% away from the current levels at $325.00.

FactSet Research has provided data showing that 31 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 2 advise that it is a overweight. 18 analysts have rated it as a buy and 11 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 26, 2022 when Goldman upgraded the stock to “Buy” and issued a price target of between $220 and $370. Stifel also upgraded the stock to “Buy” from Hold on October 13, 2022 at a price target of $223-$299. Argus upgraded its price target at $300.

The current price level is -3.21%, -2.22%, and 14.26% away from its SMA20, SMA50, and SMA200 respectively, with the BIIB price moving above the 50-day SMA on February 17. Biogen Inc. (BIIB) stock is down -2.77% over the week and -0.62% over the past month. Its price is 0.53% year-to-date and 29.75% over the past year.

The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of $4.77 above consensus estimates by $0.63. The company’s next earnings report is expected on 04/26/2023, with forecasts estimating quarterly EPS at $3.51 and $17.12 for whole year. BIIB’s earnings per share are forecast to shrink by -10.90% this year and -7.90% over next year. Expected sales for next quarter are $2.34 billion, which analysts say will come at $10.07 billion for the current fiscal year and next year at $9.38 billion. In addition, estimates put the company’s current quarterly revenue at an average of $2.44 billion.

Its 12-month price target is $325.00. To reach the target analysts have set, the stock logically needs to grow 13.62 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $249.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $388.00.

Outstanding shares total 144.40M with insiders holding 0.68% of the shares and institutional holders owning 89.42% of the company’s common stock. The company has a return on investment of 15.30% and return on equity of 24.50%. The price to earnings ratio (P/E ratio) amounts to 14.18 while the forward price to earnings ratio is 17.73. The beta has a value of 0.18. Price to book ratio is 3.15 and price to sales ratio is 3.88.

According to a U.S. Securities and Exchange Commission filing, Vanguard PRIMECAP Fund has reduced its position in Biogen Inc. (BIIB) to 8,920,561 shares, mirroring a recent drop by -0.04%. Vanguard PRIMECAP Fund dumped 3130.0 shares of Biogen Inc. common stock bringing its total worth to about $2.59 billion at the end of recent close, SEC documents show. Vanguard PRIMECAP Fund isn’t the only investment manager who changed stakes and is followed by Vanguard Health Care Fund, which sold off -0.22 million shares to end up with 4,970,503 shares worth $1.45 billion. Vanguard Total Stock Market Index raise their holdings by 0.78% in the company over the course of the most recent quarter. It now holds a 3.07% position in Biogen Inc. thanks to 4.41 million shares amounting to $1.28 billion.

Most Popular